In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback